MedTrace Logo

A Clinical Study on Kangfu Anti-inflammatory Suppository of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Evidence of Dampness and Heat Accumulation)

NCT04035785 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2019-07-29

No results posted yet for this study

Summary

To evaluate the efficacy and safety of Kangfu Xiaoyan Suppository in the treatment of pelvic inflammatory diseases (dampness-heat accumulation syndrome) and its influence on the sequelae of pelvic inflammatory diseases, and to study the role of traditional Chinese medicine in reducing the use of antibiotics and the risk of clinical medication, taking levofloxacin + metronidazole as the control drug.

Conditions

  • Pelvic Inflammatory Diseases

Interventions

DRUG

Kangfu Anti-inflammatory Suppository

To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.

Sponsors & Collaborators

  • Xiyuan Hospital of China Academy of Chinese Medical Sciences

    collaborator OTHER

  • Peking University First Hospital

    collaborator OTHER

  • Beijing Obstetrics and Gynecology Hospital

    collaborator OTHER

  • Longhua Hospital

    collaborator OTHER

  • Third Hospital of Peking University

    collaborator UNKNOWN

  • Peking Union Medical College Hospital

    collaborator OTHER

  • First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

    collaborator UNKNOWN

  • Shenzhen Maternal and Child Health Hospital

    collaborator UNKNOWN

  • First Affiliated Hospital of Heilongjiang University of Traditional Chinese

    collaborator UNKNOWN

  • Chengdu University of Traditional Chinese Medicine

    collaborator OTHER

  • China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Yanming Xie · Institute of Basic Research in Clinical Medicine, China Academy of Chinese

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-28
Primary Completion
2019-07-28
Completion
2020-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04035785 on ClinicalTrials.gov